1810
A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy.
 40-year-old man with relapsing-remitting multiple sclerosis (MS): Subject; 40-year-old: Subject.Age; man: Subject.Gender; primary central nervous system lymphoma (PCNSL): Effect; 21 doses of natalizumab monotherapy: Treatment; relapsing-remitting multiple sclerosis (MS): Treatment.Disorder; 21 doses: Treatment.Dosage; natalizumab: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 40-year-old man with relapsing-remitting multiple sclerosis (MS): Subject; 40-year-old: Subject.Age; man: Subject.Gender; primary central nervous system lymphoma (PCNSL): Effect; 21 doses of natalizumab monotherapy: Treatment; relapsing-remitting multiple sclerosis (MS): Treatment.Disorder; 21 doses: Treatment.Dosage; natalizumab: Treatment.Drug